BioventusBVS
Market Cap: 477M
About: Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Employees: 995
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 21
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
4% more funds holding
Funds holding: 80 [Q4 2023] → 83 (+3) [Q1 2024]
8% more call options, than puts
Call options by funds: $998K | Put options by funds: $925K
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2023] → 3 (+0) [Q1 2024]
8.36% less ownership
Funds ownership: 62.36% [Q4 2023] → 54.0% (-8.36%) [Q1 2024]
14% less capital invested
Capital invested by funds: $207M [Q4 2023] → $178M (-$29M) [Q1 2024]
Research analyst outlook
2 Wall Street Analysts provided 1 year price forecasts over the past 6 months
2 analyst ratings
Canaccord Genuity William Plovanic | 7%upside $8 | Buy Maintained | 8 May 2024 |
Craig-Hallum Alexander Nowak | 20%upside $9 | Buy Maintained | 13 Mar 2024 |